136 related articles for article (PubMed ID: 37124135)
1. Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma.
Stuckey R; Luzardo Henríquez H; de la Nuez Melian H; Rivero Vera JC; Bilbao-Sieyro C; Gómez-Casares MT
World J Clin Oncol; 2023 Apr; 14(4):160-170. PubMed ID: 37124135
[TBL] [Abstract][Full Text] [Related]
2. Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma.
Yaniv B; Tanenbaum B; Kazakova V; Patel SA
Leuk Res; 2024 May; 142():107519. PubMed ID: 38761562
[TBL] [Abstract][Full Text] [Related]
3. Primary Thyroid Lymphoma: Clinical Factors Predicting the Possibility of Diffuse Large B-Cell Lymphoma.
Kariya A; Tachibana T; Hiramatsu Y; Wani Y; Matsumoto JY; Furukawa C; Sato A; Naoi Y; Orita Y; Sato Y; Ando M
Ear Nose Throat J; 2023 Dec; ():1455613231218130. PubMed ID: 38078418
[No Abstract] [Full Text] [Related]
4. Expression of "DNA damage response" pathway genes in diffuse large B-cell lymphoma: The potential for exploiting synthetic lethality.
Mansoor A; Kamran H; Rizwan H; Akhter A; Roshan TM; Shabani-Rad MT; Bavi P; Stewart D
Hematol Oncol; 2024 Jan; 42(1):e3225. PubMed ID: 37795760
[TBL] [Abstract][Full Text] [Related]
5. Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review.
Decruyenaere P; Offner F; Vandesompele J
Exp Hematol Oncol; 2021 Feb; 10(1):13. PubMed ID: 33593440
[TBL] [Abstract][Full Text] [Related]
6. Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study.
Vaughn JL; Epperla N
Biomark Res; 2023 Sep; 11(1):84. PubMed ID: 37759262
[TBL] [Abstract][Full Text] [Related]
7. Alterations of 5-hydroxymethylation in circulating cell-free DNA reflect molecular distinctions of subtypes of non-Hodgkin lymphoma.
Chiu BC; Chen C; You Q; Chiu R; Venkataraman G; Zeng C; Zhang Z; Cui X; Smith SM; He C; Zhang W
NPJ Genom Med; 2021 Feb; 6(1):11. PubMed ID: 33574286
[TBL] [Abstract][Full Text] [Related]
8. Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma.
Fernández-Miranda I; Pedrosa L; González-Rincón J; Espinet B; de la Cruz Vicente F; Climent F; Gómez S; Royuela A; Camacho FI; Martín-Acosta P; Yanguas-Casás N; Domínguez M; Méndez M; Colomo L; Salar A; Horcajo B; Navarro M; García-Cosío M; Piris-Villaespesa M; Llanos M; García JF; Sequero S; Mercadal S; García-Hernández S; Navarro B; Mollejo M; Provencio M; Sánchez-Beato M
Mod Pathol; 2024 May; 37(7):100516. PubMed ID: 38763418
[TBL] [Abstract][Full Text] [Related]
9. 2024 Update: Advances in the risk stratification and management of large B-cell lymphoma.
Tavakkoli M; Barta SK
Am J Hematol; 2023 Nov; 98(11):1791-1805. PubMed ID: 37647158
[TBL] [Abstract][Full Text] [Related]
10. Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma.
Dong N; Perez-Lamas L; Chavez JC
Expert Opin Emerg Drugs; 2023 Dec; 28(3):181-190. PubMed ID: 37649373
[TBL] [Abstract][Full Text] [Related]
11. Turning the tide in aggressive lymphoma: liquid biopsy for risk-adapted treatment strategies.
Wang S; Mouliere F; Pegtel DM; Chamuleau MED
Trends Mol Med; 2024 May; ():. PubMed ID: 38692937
[TBL] [Abstract][Full Text] [Related]
12. DLBCL: Who is high risk and how should treatment be optimized?
Dabrowska-Iwanicka AP; Nowakowski GS
Blood; 2023 Nov; ():. PubMed ID: 37922443
[TBL] [Abstract][Full Text] [Related]
13. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Gil-Alós D; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
Front Immunol; 2023; 14():1349296. PubMed ID: 38268917
[TBL] [Abstract][Full Text] [Related]
14. The implication of next-generation sequencing in the diagnosis and clinical management of non-Hodgkin lymphomas.
Tomacinschii V; Mosquera Orgueira A; Santos CA; Robu M; Buruiana S; Fraga Rodriguez MF
Front Oncol; 2023; 13():1275327. PubMed ID: 38023160
[TBL] [Abstract][Full Text] [Related]
15. Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center.
Zhu ML; Drill E; Joffe E; Salles G; Delgado AR; Zelenetz A; Palomba ML; Arcila M; Dogan A
Haematologica; 2024 Mar; ():. PubMed ID: 38497151
[TBL] [Abstract][Full Text] [Related]
16. Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations.
Chan JY; Somasundaram N; Grigoropoulos N; Lim F; Poon ML; Jeyasekharan A; Yeoh KW; Tan D; Lenz G; Ong CK; Lim ST
Discov Oncol; 2023 Jul; 14(1):132. PubMed ID: 37466782
[TBL] [Abstract][Full Text] [Related]
17. Aggressive B-cell non-Hodgkin lymphomas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
Rodriguez-Pinilla SM; Dojcinov S; Dotlic S; Gibson SE; Hartmann S; Klimkowska M; Sabattini E; Tousseyn TA; de Jong D; Hsi ED
Virchows Arch; 2024 Jan; 484(1):15-29. PubMed ID: 37530792
[TBL] [Abstract][Full Text] [Related]
18. Mouse Models for HTLV-1 Infection and Adult T Cell Leukemia.
Nakajima S; Okuma K
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511495
[TBL] [Abstract][Full Text] [Related]
19. Insights into the New Molecular Updates in Acute Myeloid Leukemia Pathogenesis.
Demir D
Genes (Basel); 2023 Jul; 14(7):. PubMed ID: 37510328
[TBL] [Abstract][Full Text] [Related]
20. HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy.
Wan X; Young KH; Bai O
Front Immunol; 2023; 14():1216610. PubMed ID: 37483605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
